Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2Bone Neoplasms 1

Interventions

HhAntag691 15sonidegib 5cemiplimab 5Nivolumab 5Aminolevulinic Acid 5daromun 4Specimen Handling 4Radiotherapy 3Magnetic Resonance Spectroscopy 33-ingenyl angelate 3tazarotene 2relatlimab 2Ipilimumab 2IPI-926 2Drug Evaluation 2Celecoxib 2Biopsy 2talimogene laherparepvec 1remetinostat 1gusacitinib 1endonuclease V, phage T4 1X-Rays 1Triamcinolone 1Sutures 1Surgical Procedures, Operative 1Solutions 1Papillomavirus Vaccines 1Opdualag 1Observation 1Niacinamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Basal Cell × IPI-926 × Clear all
NCT02762084 2020-07-23

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

PellePharm, Inc.

Phase 2 Completed
17 enrolled 22 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02828111 2019-01-08

BCC

PellePharm, Inc.

Phase 2 Completed
36 enrolled 17 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡